FOLD Slowly Unfolding, EBS Continues Contract Spree, HZNP Plunges On Trial Data

Shares of Horizon Pharma plc (HZNP) plunged over 22% on failure of the company's phase III trial of Actimmune in Friedreich's ataxia to meet its primary endpoint.

from RTT - Biotech http://ift.tt/2h3BLRB
via IFTTT